Product Details
| Product Name:
Iptacopan |
CAS No.:
1644670-37-0 |
| Purity:
99.49% |
Supply Ability:
10g |
| Release date:
2026/05/11 |
Product Introduction
Bioactivity
| Name | Iptacopan |
| Description | Iptacopan (LNP023) is an inhibitor with high affinity to factor B, with a KD value of 7.9 nM and an IC50 value of 10 nM. |
| In vitro | METHODS: Blood from three patients was analyzed in 2-14 replicates and Iptacopan was used at 1 μM. Hemolysis of PNH erythrocytes was determined by FACS analysis.
RESULTS LNP023 can block C3 deposition on the surface of CD59-negative red blood cells. [2] |
| In vivo | METHODS: Iptacopan (LNP023) was tested in KRN-induced arthritis at doses of 20, 60 and 180 mg/kg by injection twice daily.
RESULTS Comprehensive disease protection was observed at 60 and 180 mg/kg, and LNP023 significantly inhibited complement activation in joints at all doses, with significant reductions in Ba, C3d, and C5a levels. [1]
METHODS: Sixty-eight patients with biopsy-proven C3G, decreased C3 (<77 mg/dl), proteinuria ≥1.0 g/g), and estimated glomerular filtration rate (eGFR) ≥30 ml/min per 1.73 m2 were recruited. Patients will be randomized 1:1 to receive iptacopan 200 mg twice daily or placebo for 6 months, followed by open-label treatment of all patients with iptacopan 200 mg twice daily for 6 months.
RESULTS Iptacopan slows disease progression by inhibiting FB and preventing excessive activation of AP and may become one of the first targeted therapies available for C3G patients. [3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (11.83 mM), Sonication is recommended.
DMSO : 255 mg/mL (603.52 mM), Sonication is recommended.
|
| Keywords | LNP-023 | LNP 023 | Iptacopan |
| Inhibitors Related | EG01377 2HCl | Iptacopan hydrochloride | BCX 1470 hydrochloride | Complement C5-IN-1 | Avacopan | ADH-503 | CP-289 | Dexamethasone acetate | Dexamethasone | Cyclosporin A | Dextran sulfate sodium salt (MW 5000) | 3-Phenoxybenzaldehyde |
| Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | ReFRAME Related Library | Drug-induced Liver Injury (DILI) Compound Library | Toxic Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$10.00
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-26 |
|
|
$51.00
|
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-22 |
|
|
$3.00
|
VIP2Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2026-04-17 |
United States